StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

Analysts at StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Down 1.4%

Check-Cap stock opened at $0.88 on Tuesday. Check-Cap has a 12-month low of $0.56 and a 12-month high of $3.04. The firm has a 50-day moving average price of $0.78 and a 200-day moving average price of $0.91. The firm has a market capitalization of $5.15 million, a PE ratio of -0.29 and a beta of 0.21.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.